{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:57:45Z","timestamp":1781611065688,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Diabetes mellitus (DM) is a chronic metabolic disorder marked by persistent hyperglycemia. While HbA1c has traditionally been used to assess glycemic control, growing evidence highlights glycemic variability (GV) and Time in Range (TIR) as more precise indicators of glucose fluctuations, which are linked to diabetic complications, especially chronic kidney disease (CKD). Emerging combination therapies targeting different pathophysiologic mechanisms of type 2 diabetes mellitus (T2DM), such as SGLT2 inhibitors and DPP-4 inhibitors, offer promise in reducing GV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy of three commonly prescribed fixed-dose combination (FDC) therapies\u2014Teneligliptin + Dapagliflozin (Arm-A), Sitagliptin + Dapagliflozin (Arm-B), and Linagliptin + Empagliflozin (Arm-C)\u2014in improving glycemic control and renal parameters in Indian T2DM patients using continuous glucose monitoring (CGM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This prospective, comparative study enrolled 90 patients (30 in each arm). CGM was used to evaluate glycemic parameters including TIR, TAR, TBR, MAGE, LAGE, MPPGE, HbA1c, FPG, PPG, and renal function indicators (eGFR, serum creatinine, BUN) at baseline and study conclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All arms demonstrated significant improvements in TIR, MAGE, LAGE, HbA1c, FPG, and PPG (p&lt;0.001). Arm-A showed a significantly superior reduction in TAR and MPPGE compared to Arm-B (p=0.029 and p=0.040, respectively) and also outperformed Arm-B in reducing FPG (p=0.042). Renal function improved comparably across arms, with a significant decline in serum creatinine noted in Arm-A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>All three FDC therapies significantly improved glycemia, with the Teneligliptin + Dapagliflozin combination offering slightly superior efficacy in reducing TAR, MPPGE, and FPG. These findings support its clinical utility in reducing glycemic variability in patients with T2DM in India. Although favorable trends were observed in renal parameters, the study duration was too short to draw definitive conclusions regarding renal safety. As such, references to renal outcomes should be interpreted with caution, and further long-term studies are warranted to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40842-025-00244-6","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T23:03:00Z","timestamp":1764111780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Triple arm, prospective, real-world study comparing the efficacy of FDC teneligliptin + dapagliflozin to FDC sitagliptin + dapagliflozin, and FDC linagliptin + empagliflozin in Indian type 2 diabetes mellitus patients using CGM device: the Amplify-TIR study"],"prefix":"10.1186","volume":"11","author":[{"given":"Suhas","family":"Erande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namdev","family":"Jagtap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. S. Praveen","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod Kumar","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Bhushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rujuta","family":"Gadkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Choudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiprasad","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmant","family":"Barkate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"244_CR1","doi-asserted-by":"publisher","unstructured":"MdJ H, Md A-M, MdR I. Diabetes mellitus, the fastest growing global public health concern: early detection should be focused. Health Sci Rep. 2024;7(3). https:\/\/doi.org\/10.1002\/hsr2.2004.","DOI":"10.1002\/hsr2.2004"},{"key":"244_CR2","doi-asserted-by":"publisher","unstructured":"Zhou Z, Sun B, Huang S, Zhu C, Bian M. Glycemic variability: adverse clinical outcomes and how to improve it? Cardiovasc diabetol. 2020;19(1). https:\/\/doi.org\/10.1186\/s12933-020-01085-6.","DOI":"10.1186\/s12933-020-01085-6"},{"issue":"1","key":"244_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jdi.14112","volume":"15","author":"Y Mo","year":"2023","unstructured":"Mo Y, Lu J, Zhou J. Glycemic variability: measurement, target, impact on complications of diabetes and does it really matter? J Diabetes investig. 2023;15(1):5\u201314. https:\/\/doi.org\/10.1111\/jdi.14112.","journal-title":"J Diabetes investig"},{"issue":"1","key":"244_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/dia.2020.0030","volume":"23","author":"T Blevins","year":"2021","unstructured":"Blevins T, Lane W, Rodbard D, et al. Glucose variability and Time in range in type 2 diabetes treated with U-500R by pump or injection: CGM findings from the VIVID study. Diabetes Technol & Ther. 2021;23(1):51\u201358. https:\/\/doi.org\/10.1089\/dia.2020.0030.","journal-title":"Diabetes Technol & Ther"},{"issue":"2","key":"244_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2337\/cd24-aint","volume":"42","author":"NA ElSayed","year":"2024","unstructured":"ElSayed NA, Baig A, Bradley S, et al. Introduction: standards of care in diabetes-2024 abridged for primary care professionals. Clin Diabetes. 2024;42(2):181\u2013181. https:\/\/doi.org\/10.2337\/cd24-aint.","journal-title":"Clin Diabetes"},{"issue":"2","key":"244_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13300-022-01355-4","volume":"14","author":"V Mohan","year":"2023","unstructured":"Mohan V, Joshi SR, Mithal A, et al. Expert consensus recommendations on Time in range for monitoring glucose levels in people with diabetes. An Indian Perspect. 2023;14(2):237\u201349. https:\/\/doi.org\/10.1007\/s13300-022-01355-4.","journal-title":"An Indian Perspect"},{"key":"244_CR7","doi-asserted-by":"publisher","first-page":"110117","DOI":"10.1016\/j.diabres.2022.110117","volume":"193","author":"HH Habte-Asres","year":"2022","unstructured":"Habte-Asres HH, Murrells T, Nitsch D, Wheeler DC, Forbes A. Glycaemic variability and progression of chronic kidney disease in people with diabetes and comorbid kidney disease: Retrospective cohort study. Diabetes Res Clin Pr. 2022;193:110117\u2013110117. https:\/\/doi.org\/10.1016\/j.diabres.2022.110117.","journal-title":"Diabetes Res Clin Pr"},{"issue":"4","key":"244_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4093\/dmj.2015.39.4.273","volume":"39","author":"S Suh","year":"2015","unstructured":"Suh S, Kim JH. Glycemic variability: How do we measure it and why is it important? Diabetes Metab J. 2015;39(4):273. https:\/\/doi.org\/10.4093\/dmj.2015.39.4.273.","journal-title":"Diabetes Metab J"},{"key":"244_CR9","doi-asserted-by":"publisher","unstructured":"Chadha M, Das AK, Deb P, et al. Expert opinion: optimum clinical approach to combination-use of SGLT2i + DPP4i in the Indian diabetes setting. Diabetes Ther. https:\/\/doi.org\/10.1007\/s13300-022-01219-x. Published online March 25, 2022.","DOI":"10.1007\/s13300-022-01219-x"},{"issue":"3","key":"244_CR10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/dom.13879","volume":"22","author":"KY Cho","year":"2019","unstructured":"Cho KY, Nomoto H, Nakamura A, et al. Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: an open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). Diabetes Obes Metab. 2019;22(3):458\u201362. https:\/\/doi.org\/10.1111\/dom.13879.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"244_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4093\/dmj.2021.0016","volume":"46","author":"JC Bae","year":"2022","unstructured":"Bae JC, Kwak SH, Kim HJ, et al. Effects of Teneligliptin on HbA1c levels, continuous glucose monitoring-derived Time in range and glycemic variability in elderly patients with T2DM (TEDDY study). Diabetes Metab J. 2022;46(1):81\u201392. https:\/\/doi.org\/10.4093\/dmj.2021.0016.","journal-title":"Diabetes Metab J"},{"key":"244_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6666403","volume":"2020","author":"M Luo","year":"2020","unstructured":"Luo M, Kong X, Wang H, et al. Effect of Dapagliflozin on glycemic variability in patients with type 2 diabetes under insulin Glargine combined with other oral hypoglycemic drugs. J Diabetes Res. 2020;2020:1\u20137. https:\/\/doi.org\/10.1155\/2020\/6666403.","journal-title":"J Diabetes Res"},{"issue":"1","key":"244_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215\u201324. https:\/\/doi.org\/10.1016\/j.kint.2021.03.033.","journal-title":"Kidney Int"},{"issue":"2","key":"244_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4103\/jod.jod_19_24","volume":"15","author":"S Ray","year":"2024","unstructured":"Ray S, Ezhilan J, Karnik R, Prasad A, Dhar R. Expert opinion on fixed dose combination of dapagliflozin plus sitagliptin for unmet cardiovascular benefits in type 2 diabetes mellitus. J Educ Chang diabetology. 2024;15(2):131\u201341. https:\/\/doi.org\/10.4103\/jod.jod_19_24.","journal-title":"J Educ Chang diabetology"},{"issue":"18","key":"244_CR15","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.3390\/jcm10184078","volume":"10","author":"H Lee","year":"2021","unstructured":"Lee H, Park S, Kim EY. Glycemic variability impacted by SGLT2 inhibitors and GLP 1 agonists in patients with diabetes mellitus: a systematic review and meta-analysis. J Clin Med. 2021;10(18):4078. https:\/\/doi.org\/10.3390\/jcm10184078.","journal-title":"J Clin Med"},{"key":"244_CR16","doi-asserted-by":"publisher","unstructured":"Lee S, Lee H, Kim Y, Kim E. Effect of DPP-IV inhibitors on glycemic variability in patients with T2DM: a systematic review and meta-analysis. Sci Rep. 2019;9(1). https:\/\/doi.org\/10.1038\/s41598-019-49803-9.","DOI":"10.1038\/s41598-019-49803-9"},{"key":"244_CR17","doi-asserted-by":"publisher","unstructured":"Kesavadev J, Misra A, Saboo B, et al. Time-in-range and frequency of continuous glucose monitoring: recommendations for South Asia. Diabetes & Metabolic Syndr: Clin Res & Rev. Published online November 22, 2021: 102345. doi: https:\/\/doi.org\/10.1016\/j.dsx.2021.102345.","DOI":"10.1016\/j.dsx.2021.102345"},{"issue":"12","key":"244_CR18","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s13300-020-00928-5","volume":"11","author":"T Ishikawa-Tanaka","year":"2020","unstructured":"Ishikawa-Tanaka T, Hosojima M, Kabasawa H, et al. Effects of DPP-4 inhibitors on blood glucose variability in Japanese patients with type 2 diabetes on maintenance hemodialysis: a prospective observational exploratory study. Diabetes Ther. 2020;11(12):2845\u201361. https:\/\/doi.org\/10.1007\/s13300-020-00928-5.","journal-title":"Diabetes Ther"},{"issue":"6","key":"244_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/JAMPS\/2023\/v25i6621","volume":"25","author":"S Bhattacharyya","year":"2023","unstructured":"Bhattacharyya S, Muchhala S, Jhaveri K. Efficacy of fixed-dose combination of Dapagliflozin and sitagliptin in type 2 diabetes mellitus using continuous glucose monitoring: a real-world study in India. J Adv Med Pharm Sci. 2023;25(6):1\u20139. https:\/\/doi.org\/10.9734\/JAMPS\/2023\/v25i6621.","journal-title":"J Adv Med Pharm Sci"},{"issue":"8","key":"244_CR20","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1111\/dom.15089","volume":"25","author":"K Takuma","year":"2023","unstructured":"Takuma K, Fuchigami A, Shigiyama F, Kumashiro N, Hirose T. Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub-analysis of the DIVERSITY-CVR study. Diabetes Obes Metab. 2023;25(8):2131\u201341. https:\/\/doi.org\/10.1111\/dom.15089.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"244_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s13340-016-0258-y","volume":"7","author":"K Tanaka","year":"2016","unstructured":"Tanaka K, Okada Y, Mori H, et al. Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study. Diabetol Int. 2016;7(4):368\u201374. https:\/\/doi.org\/10.1007\/s13340-016-0258-y.","journal-title":"Diabetol Int"},{"key":"244_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.29011\/2638-003X.100116","volume":"8","author":"A Petare","year":"2024","unstructured":"Petare A, Joshi S, Das AK, Gadve S, Mavani SS. An observational retrospective real-world study to evaluate the effect of Teneligliptin on parameters of renal function, glycemic control, and safety in Indian T2DM patients with chronic kidney disease (TOP RENAL). Curr Trends Intern Med. 2024;8:216. https:\/\/doi.org\/10.29011\/2638-003X.100116.","journal-title":"Curr Trends Intern Med"},{"issue":"6","key":"244_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/dom.12281","volume":"16","author":"PH Groop","year":"2014","unstructured":"Groop PH, Del Prato S, Taskinen MR, et al. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab. 2014;16(6):560\u201368. https:\/\/doi.org\/10.1111\/dom.12281.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"244_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2337\/dc12-0706","volume":"36","author":"JB McGill","year":"2012","unstructured":"McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of Linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2012;36(2):237\u201344. https:\/\/doi.org\/10.2337\/dc12-0706.","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"244_CR25","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2024;48(Supplement_1):S181\u2013206. https:\/\/doi.org\/10.2337\/dc25-S009.","journal-title":"Diabetes Care"},{"issue":"11","key":"244_CR26","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386. https:\/\/doi.org\/10.2337\/dci22-0034.","journal-title":"Diabetes Care"},{"issue":"5","key":"244_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","volume":"29","author":"SL Samson","year":"2023","unstructured":"Samson SL, Vellanki P, Blonde L, et al. American association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. Endocr Pract: Off J Am Coll of Endocrinol and the Am Assoc of Clin Endocrinologists. 2023;29(5):305\u201340. https:\/\/doi.org\/10.1016\/j.eprac.2023.02.001.","journal-title":"Endocr Pract: Off J Am Coll Of Endocrinol And The Am Assoc Of Clin Endocrinologists"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00244-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-025-00244-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00244-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:49:55Z","timestamp":1781610595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-025-00244-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["244"],"URL":"https:\/\/doi.org\/10.1186\/s40842-025-00244-6","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The work presented in this study was in accordance with the study protocol, the New Drugs and Clinical Trials Rules 2019 issued by the Government of India, the ethical principles that have their origin in the Declaration of Helsinki, International Council for Harmonisation (ICH) Good Clinical Practice (GCP), and all applicable local regulatory requirements. Informed consent was obtained from all the study subjects who took part in the trial. Ethics committee approval was obtained from all respective sites and study was registered in CTRI (CTRI\/2023\/05\/053178).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"32"}}